AGIO earnings call for the period ending March 31, 2019.
News & Analysis: Agios Pharmaceuticals
AGIO earnings call for the period ending December 31, 2018.
If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
On a positive day for the market, these stocks outperformed. Find out why.
Short-sellers have piled on Agios, Insys, Intercept, Lexicon, and Myriad Genetics. But are they wrong?
Funding isn't a big concern for these three drug developers.
It was a roller-coaster year for investors in the clinical-stage biotech. Here's a review of the year's key headlines that caused shares to drop.
The biotech is left without a backup plan.
Flexion Therapeutics, Kite Pharma, and Agios Pharma all have drugs that could make their way to the FDA in the coming months.
The biotech is the big loser from the American Society of Hematology meeting.